In an 83-year-old woman with increased anxiety, is citalopram (Celexa) appropriate or is escitalopram (Lexapro) a better option for her medication refill?

Lexapro (escitalopram) is the better choice for this 83-year-old woman with anxiety.

Primary Recommendation

For an 83-year-old patient with increased anxiety, prescribe escitalopram (Lexapro) 5-10 mg daily rather than citalopram (Celexa). The critical issue here is cardiac safety: both the FDA and EMA have imposed dose restrictions on citalopram specifically due to QT prolongation risk, with maximum doses further reduced for patients over 60 years of age 1. Citalopram carries a documented risk of QT prolongation associated with Torsade de Pointes, ventricular tachycardia, and sudden death, particularly at doses exceeding 40 mg/day, and should be avoided in patients with long QT syndrome 2.

Why Escitalopram is Superior in Elderly Patients

Cardiac Safety Profile

• Escitalopram has lower QT prolongation risk compared to citalopram 1
• While both SSRIs carry some cardiac risk (OR 1.21 for cardiac arrest in SSRI users, mean age 74 years), citalopram specifically has been flagged by regulatory agencies for dose-dependent QT effects 1
• Escitalopram/citalopram have the least effect on CYP450 isoenzymes compared to other SSRIs, reducing drug-drug interaction potential 2—important in elderly patients on multiple medications

Efficacy for Anxiety

• Escitalopram is FDA-approved for generalized anxiety disorder in adults, with demonstrated efficacy in three 8-week placebo-controlled trials 3
• In elderly patients specifically (≥65 years) with comorbid depression and anxiety, escitalopram 10-20 mg/day showed significant improvements in both Hamilton Anxiety Scale scores (effect size = 1.83) and was well-tolerated 4
• Citalopram also shows efficacy for late-life anxiety (65% response rate vs 24% placebo in patients ≥60 years) 5, but the cardiac safety concerns outweigh this benefit

Tolerability in the Elderly

• In the elderly anxiety study, only 15% withdrew from escitalopram treatment (1 for lack of efficacy, 2 for adverse events: dizziness and somnolence) 4
• Most common problematic side effect with citalopram in elderly was sedation 5
• Both drugs carry fall risk in elderly patients—a 2025 geriatric guideline found increased fall risk with SSRIs (RR 1.78) 6

Dosing Algorithm for This Patient

Start escitalopram 5 mg daily (use the 5 mg tablet formulation available) 3:

• This subtherapeutic "test dose" is advisable because initial adverse effects of SSRIs can include anxiety or agitation 2
• After 1 week, if tolerated, increase to 10 mg daily—the standard therapeutic dose for anxiety
• Maximum dose in elderly: 10 mg daily (do not exceed this in patients >60 years due to cardiac concerns)
• Reassess at weeks 1,2,4,6, and 8

Critical Safety Monitoring

Before Starting Treatment

• Obtain baseline ECG if any cardiac risk factors present (given age alone, this is reasonable)
• Review all current medications for QT-prolonging drugs or serotonergic agents
• Assess fall risk and implement fall precautions

During Treatment

• Monitor for serotonin syndrome (confusion, agitation, tremors, hyperreflexia, autonomic instability)—can occur within 24-48 hours of starting, especially if on other serotonergic drugs 2
• Watch for hyponatremia/SIADH (more common in elderly)
• Assess for increased fall risk and provide counseling
• Monitor for paradoxical anxiety worsening in first 1-2 weeks

Common Pitfalls to Avoid

1. Do NOT use citalopram >20 mg/day in patients >60 years due to dose-dependent QT prolongation 1
2. Do NOT abruptly discontinue—escitalopram has lower discontinuation syndrome risk than paroxetine but still requires tapering 2
3. Do NOT combine with other serotonergic drugs without careful monitoring (tramadol, triptans, other antidepressants, St. John's Wort) 2
4. Avoid benzodiazepines if possible—the 2025 geriatric guidelines show benzodiazepines (especially midazolam) pose excessive risk in elderly with serious adverse events in 16.8% of older adults 6

Alternative Considerations

If SSRIs fail or are contraindicated:

• SNRIs showed NO association with cardiac arrest in the Danish registry study (unlike SSRIs with OR 1.21) 1
• However, escitalopram remains first-line for anxiety given FDA approval and elderly-specific efficacy data

Expected Timeline

• Anxiety improvement typically begins at 2-4 weeks
• Full therapeutic effect by 6-8 weeks
• If no response by 8 weeks at 10 mg daily, consider switching drug classes rather than increasing dose due to age-related cardiac concerns